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Hillary A. Keenan, Susan Bonner-Weir, and George L. King
W
e appreciate the response by Rother and
Harlan (1) to our article (2). However, it is
difﬁcult to understand what the conﬁrmatory
aspects of the Medalist Study data are with
respect to the studies of Liu et al. (3) and Rother et al. (4),
which documented minimal levels of C-peptide production
in individuals with a diabetes duration of 19.2  11.8 years
and 21.3  10.7 years, respectively. Clearly, this duration is
signiﬁcantly lower than the Medalists’ mean duration of
56.2  5.8 years. Another difference is the relationship of
disease duration and residual C-peptide production, which
was not signiﬁcant in the Medalist Study but was reported
to be signiﬁcant in the article by Liu et al., with a
statistically higher mean duration (P  0.0045) in those
patients without (26.2  13.1 years) than those patients
with residual C-peptide production (19.2  11.8 years) (3).
One of the most important components of our study is
the pre- and post mortem data on nine Medalists. Ours is
the ﬁrst study to show a correlation between random
C-peptide, physiological response to stimulation, and in-
sulin positive -cell mass in any human population of type
1 diabetic patients and, extraordinarily, in individuals with
a mean of 55 years of diabetes. Although this part of the
study included only nine patients, each had insulin posi-
tive cells even after their extreme duration of diabetes.
Although our ﬁndings of stimulated C-peptide may be an
underestimation of islet secretory capacity as suggested
by Rother and Harlan, because of exogenous insulin
injection before the mixed-meal tolerance test, only 6 of
the 31 subjects took insulin the morning of the test, and
that was to bring their fasting blood glucose values to
under 250 mg/dl, a safe range for the test to be performed.
We hope these explanations have provided a clear differ-
entiation between our Medalist Study and previous
publications.
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